Management of the critically ill patient with severe sepsis

Journal of Chemotherapy

Volumn 11, Issue 6, 1999, Pages 524-529

  Vincent, J L ^a   Preiser, J C ^b  

^a ERASME HOSPITAL   (Belgium)

^b NONE

Author keywords

Enteral nutrition; Resuscitation; Septic shock; Tissue oxygenation; Vasopressors

Indexed keywords

CONFERENCE PAPER; CRITICAL ILLNESS; FLUID BALANCE; HEART FUNCTION; HUMAN; IMMUNE STATUS; LUNG VENTILATION; MORBIDITY; MORTALITY; NUTRITIONAL SUPPORT; SEPSIS; TISSUE OXYGENATION;

EID: 0033397209     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1999.11.6.524     Document Type: Conference Paper

References (51)

1. 1 Vincent JL. Definition and pathogenesis of septic shock. Curr Top Microbiol Immunol 1996; 216: 1-13.
2. 2 Yao YM, Redl H, Bahrami S, Schlag G. The inflammatory basis of trauma/shock-associated multiple organ failure. Inflamm Res 1998; 47: 201-10.
3. 3 Murphy K, Haudek SB, Thompson M, Giroir BP. Molecular biology of septic shock. New Horiz 1998; 6: 181-93.
4. 4 Koch T. Origin and mediators involved in sepsis and the systemic inflammatory response syndrome. Kidney Int Suppl 1998; 64: S66-S69.
5. 5 Vincent JL, Gris P, Coffernils M, et al. Myocardial depression characterizes the fatal course of septic shock. Surgery 1992; 111: 660-7.
6. 6 Stahl GL, Lefer AM. Mechanisms of platelet-activating factor-induced cardiac depression in the isolated perfused rat heart. Circ Shock 1987; 23: 165-77.
7. 7 Walley KR, Hebert PC, Wakai Y, Wilcox PG, Road JD, Cooper DJ. Decrease in left ventricular contractility after tumor necrosis factor-α infusion in dogs. J Appl Physiol 1994; 7660: 1060-7.
8. 8 Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo JE. Tumor necrosis factor and interleukin Iβ are responsible for in vitro myocardial depression induced by human septic shock serum. J Exp Med 1996; 183: 949-58.
9. 9 Sun X, Delbridge LM, Dusting GJ. Cardiopressant effects of interferon-gamma and endotoxin reversed by inhibition of NO synthase 2 in rat myocardium. J Mol Cell Cardiol 1998; 30: 989-97.
10. 10 Kumar A, Brar R, Wang P, et al. Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility. Am J Physiol 1999; 276: R265-R276.
11. 11 Weil MH, Shubin H. The "VIP" approach to the bedside management of shock. JAMA 1969; 207: 337-40.
12. 12 Schierhout G, Roberts I. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomised trials. Br Med J 1998; 316: 961-4.
13. 13 Choi PT, Yip G, Quinonez LG, Cook DJ. Crystalloids vs. colloids in fluid resuscitation: a systematic review. Crit Care Med 1999; 27: 200-10.
14. 14 Van der Linden P, Gilbert E, Paques P, Simon C, Vincent JL. Influence of hematocrit on tissue O2 extraction capabilities in anesthetized dogs during acute hemorrhage. Am J Physiol 1993; 264: H1942-H1947.
15. 15 Spence RK, Carson JA, Poses R, et al. Elective surgery without transfusion: influence of preoperative hemoglobin level and blood loss on mortality. Am J Surg 1990; 159: 320-4.
16. 16 Bush RL, Pevec WC, Holcroft JW. A prospective, randomized trial limiting perioperative red blood cell transfusions in vascular patients. Am J Surg 1997; 174: 143-8.
17. 17 Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999; 340: 409-17.
18. 18 Carson JL, Duff A, Poses RM, et al. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet 1996; 348: 1055-60.
19. 19 Silva E, De Backer D, Creteur J, Vincent JL. Effects of vasoactive drugs on gastric intramucosal pH. Crit Care Med 1998; 26: 1749-58.
20. 20 Meier-Hellmann A, Reinhart K, Bredle DL, Specht M, Spies CD, Hannemann L. Epinephrine impairs splanchnic perfusion in septic shock. Crit Care Med 1997; 25: 399-404.
21. 21 Shoemaker WC, Appel PL, Kram HB, Waxman K, Lee TS. Prospective trial of supranormal values of survivors as therapeutic goals in high-risk surgical patients. Chest 1988; 94: 1176-86.
22. 22 Shoemaker WC, Appel PL, Kram HB. Role of oxygen debt in the development of organ failure sepsis, and death in high-risk surgical patients. Chest 1992; 102: 208-15.
23. 23 Fleming A, Bishop M, Shoemaker WC, et al. Prospective trial of supranormal values as goals of resuscitation in severe trauma. Arch Surg 1992; 127: 1175-81.
24. 24 Boyd O, Grounds RM, Bennett ED. The beneficial effect of supranormalization of oxygen delivery with dopexamine hydrochloride on perioperative mortality. JAMA 1993; 270: 2699-707.
25. 25 Bishop MH, Shoemaker WC, Appel PL, et al. Prospective, randomized trial of survivor values of cardiac index, oxygen delivery, and oxygen consumption as resuscitation endpoints in severe trauma. J Trauma 1995; 38: 780-7.
26. 26 Hayes MA, Timmins AC, Yau EH, Palazzo M, Hinds CJ, Watson D. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994; 330: 1717-22.
27. 27 Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. N Engl J Med 1995; 333: 1025-32.
28. 28 Bone RC, Balk RA, Fein AM, et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med 1995; 23: 994-1006.
29. 29 The National Committee for the Evaluation of Centoxin. The French national registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. Arch Intern Med 1994; 154: 2484-91.
30. 30 Abraham E, Anzueto A, Gutierrez G, et al. Doubleblind randomised controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock. Lancet 1998; 351: 929-33.
31. 31 Reinhart K, RAMSES Study Group. Treatment of severe sepsis in patients with highly elevated IL-6 levels with anti-TNF monoclonal antibody MAK 195F: The RAMSES study [Abstract]. Crit Care 1998; 2: P18
32. 32 Fisher CJ, Jr., Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 1996; 334: 1697-702.
33. 33 Abraham E, Glauser MP, Butler T, et al. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. J A M A 1997; 277: 1531-8.
34. 34 Opal SM, Fisher CJ, Jr., Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1997; 25: 1115-24.
35. 35 Wasserman D, Ioannovich JD, Hinzmann RD, Deichsel G, Steinmann GG. Interferon-gamma in the prevention of severe burn-related infections: a European phase III multicenter trial. Crit Care Med 1998; 26: 434-9.
36. 36 Heard SO, Fink MP, Gamelli RL, et al. Effect of prophylactic administration of recombinant human granulocyte colony-stimulating factor (filgrastim) on the frequency of nosocomial infections in patients with acute traumatic brain injury or cerebral hemorrhage. Crit Care Med 1998; 26: 748-54.
37. 37 Reinhart K, Wiegand-Löhnert C, Grimminger F, et al. Assessment of the safety and efficacy of the monoclonal antitumor necrosis factor antibody fragment, MAK195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose ranging study. Crit Care Med 1996; 24: 733-42.
38. 38 Fisher CJ, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA 1994; 271: 1836-43.
39. 39 Baudo F, Caimi TM, deCataldo E, et al. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled, double-blind, randomized, multicenter study. Intensive Care Med 1998; 24: 336-42.
40. 40 Dhainaut JF, Tenaillon A, Le Tulzo Y, et al. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Crit Care Med 1994; 22: 1720-8.
41. 41 Fein AM, Bernard GR, Criner GJ, et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, delibant (CP-0127). JAMA 1997; 277: 482-7.
42. 42 Döcke WD, Randow F, Syrbe HP, et al. Monocyte deactivation in septic patients: restoration by IFN-g treatment. Nature Med 1997; 3: 678-81.
43. 43 Marie C, Muret J, Fitting C, Losser MR, Payen D, Cavaillon JM. Reduced ex vivo interleukin-8 production by neutrophils in septic and nonseptic systemic inflammatory response syndrome. Blood 1998; 91: 3439-46.
44. 44 Grahm TW, Zadrozny DB, Harrington T. The benefits of early jejunal hyperalimentation in the head-injured patient. Neurosurgery 1989; 25: 729-35.
45. 45 Hasse JM, Blue LS, Liepa GU, et al. Early enteral nutrition support in patients undergoing liver transplantation. J Parenter Enteral Nutr 1995; 19: 437-43.
46. 46 Carr CS, Ling KD, Boulos P, Singer M. Randomised trial of safety and efficacy of immediate postoperative enteral feeding in patients undergoing gastrointestinal resection. Br Med J 1996; 312: 869-71.
47. 47 Revelly JP, Tappy L, Berger MM, Gersbach PH, Cayeux C, Chioléro R. Hemodynamic effects of early enteral nutrition in postoperative cardiac patients with low cardiac output [Abstract]. Am J Respir Crit Care Med 1999; 159: A521
48. 48 Kemen M, Senkal M, Homann H-H, et al. Early postoperative enteral nutrition with arginine-omega-3 fatty acids and ribonucleic acid-supplemented diet versus placebo in cancer patients: An immunologic evaluation of impact. Crit Care Med 1995; 23: 652-9.
49. 49 Kudsk KA, Minard G, Croce MA, et al. A randomized trial of isonitrogenous enteral diets after severe trauma: an immune-enhancing diet reduces septic complications. Ann Surg 1996; 224: 531-43.
50. 50 Heys SD, Walker LG, Smith I, Eremin O. Enteral nutritional supplementation with key nutrients in patients with critical illness and cancer: a meta-analysis of randomized controlled clinical trials. Ann Surg 1999; 229: 467-77.
51. 51 Braga M, Gianotti L, Radaelli G, et al. Perioperative immunonutrition in patients undergoing cancer surgery: results of a randomized double-blind phase 3 trial. Arch Surg 1999; 134: 428-33.